# EDGAR Filing Document

**Accession Number:** 0001585364
**File Stem:** 0001585364-23-000011
**Filing Date:** 2023-3
**Character Count:** 9718
**Document Hash:** 3bb0ca3c4767bc2d28d0a1e3a77ba86e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001585364-23-000011.hdr.sgml**: 20230307

**ACCESSION NUMBER**: 0001585364-23-000011

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230303

**FILED AS OF DATE**: 20230307

**DATE AS OF CHANGE**: 20230307

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Quinn Grainne
- **CENTRAL INDEX KEY:** 0001679915

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36353
- **FILM NUMBER:** 23712330

**MAIL ADDRESS:**
- **STREET 1:** PERRIGO COMPANY PLC
- **STREET 2:** 515 EASTERN AVENUE
- **CITY:** ALLEGAN
- **STATE:** MI
- **ZIP:** 49010
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PERRIGO Co plc
- **CENTRAL INDEX KEY:** 0001585364
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** L2
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** THE SHARP BUILDING
- **STREET 2:** HOGAN PLACE
- **CITY:** DUBLIN 2
- **STATE:** L2
- **ZIP:** D02 TY74
- **BUSINESS PHONE:** 269-673-8451

**MAIL ADDRESS:**
- **STREET 1:** 515 EASTERN AVENUE
- **CITY:** ALLEGAN
- **STATE:** MI
- **ZIP:** 49010

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PERRIGO Co Ltd
- **DATE OF NAME CHANGE:** 20130828

## Ex-24

```
<pre>
The undersigned hereby constitutes and appoints each of Todd W. Kingma, Ryan Bradtke and
Victor Torres, signing singly, as the undersigned's true and lawful attorney-in-fact to:
(1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer
and/or director of Perrigo Company plc (the "Company"), Forms 3, 4 and 5 in accordance
with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;
(2) do and perform any and all acts for and on behalf of the undersigned that may be
necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and
execute any amendment thereto, and timely file such form with the United States
Securities and Exchange Commission and any stock exchange or similar authority; and
(3) take any other action of any type whatsoever in connection with the foregoing which, in
the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally
required by, the undersigned, it being understood that the documents executed by such
attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be
in such form and shall contain such terms and conditions as such attorney-in-fact may
approve in such attorney-in-fact's discretion.
The undersigned hereby grants to each such attorney-in-fact full power and authority to do any
and all things and take any and all actions necessary in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or could do if personally
present, with full power of substitution or revocation, hereby ratifying and confirming all that such
attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done
by virtue of this power of attorney and the rights and powers herein granted. The undersigned
acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the
undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities
to comply with Section 16 of the Securities Exchange Act of 1934.
This Power of Attorney shall remain in full force and effect until the undersigned is no longer
required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in
securities issued by the Company, unless earlier revoked by the undersigned in a signed writing
delivered to the foregoing attorneys-in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of _9/29/2020
Grainne Quinn
EVP, Chief Medical Officer
</pre>
```

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Quinn Grainne<br><sub>(Last) (First) (Middle)</sub><br>PERRIGO COMPANY PLC<br>515 EASTERN AVENUE<br><sub>(Street)</sub><br>ALLEGAN, MI 49010<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2023-03-03 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_EVP, Chief Medical Officer_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>PERRIGO Co plc [ PRGO ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Ordinary Shares | 2023-03-03 |  | A<sup>(1)</sup> |  | 5419 | A | $38.75 | 14537 | D |  |
| Ordinary Shares | 2023-03-03 |  | F |  | 2818 | D | $38.75 | 11719 | D |  |
| Ordinary Shares | 2023-03-03 |  | M<sup>(2)</sup> |  | 1052 | A | $38.75 | 12771 | D |  |
| Ordinary Shares | 2023-03-03 |  | F |  | 548 | D | $38.75 | 12223 | D |  |
| Ordinary Shares | 2023-03-03 |  | M<sup>(3)</sup> |  | 1584 | A | $38.75 | 13807 | D |  |
| Ordinary Shares | 2023-03-03 |  | F |  | 824 | D | $38.75 | 12983 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Restricted Stock Units | <sup>(4)</sup> | 2023-03-03 |  | M<sup>(2)</sup> |  |  | 1052 | <sup>(5)</sup> | <sup>(5)</sup> | Ordinary Shares | 1052.0 | <sup>(4)</sup> | 0 | D |  |
| Restricted Stock Units | <sup>(4)</sup> | 2023-03-03 |  | M<sup>(3)</sup> |  |  | 1584 | <sup>(6)</sup> | <sup>(6)</sup> | Ordinary Shares | 1584.0 | <sup>(4)</sup> | 1583 | D |  |

---

### Footnotes:

(1) Vesting of performance-based restricted stock units granted on March 5, 2020.

(2) Vesting of service-based restricted stock units granted on March 5, 2020.

(3) Vesting of service-based restricted stock units granted on March 5, 2021.

(4) Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share.

(5) Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting in 3 equal annual installments beginning 5 March 2021.

(6) Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting in 3 equal annual installments beginning 5 March 2022.

**Signature:** /s/ Victor Torres, attorney-in-fact for Ms. Grainne Quinn  
**Date:** 2023-03-07

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**